A Phase 3, Randomized, Open-Label, Multi-Country Study to Evaluate the
Research payments
$783,850
Through program year 2024, $783,850 in research payments was reported against A Phase 3, Randomized, Open-Label, Multi-Country Study to Evaluate the, across 135 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $11,289 | 11 |
| 2023 | Research | $772,561 | 124 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Matthew Davis Rochester, NY Named on 11 payments
- Charles Andrews San Antonio, TX Named on 11 payments
- Charles Fogarty Spartanburg, SC Named on 10 payments
- Terry Poling Wichita, KS Named on 10 payments
- Daniel Johnson Imperial Beach, CA Named on 9 payments
- Anton Grasch Wenatchee, WA Named on 9 payments
- Hubert Reyes Evansville, IN Named on 8 payments
- Richard Mills Mt Pleasant, SC Named on 8 payments
- Martha Fanning Kansas City, MO Named on 7 payments
- Harry Studdard Mobile, AL Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.